Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00743028 | Assess the Oral Bioavailability of New ABT-263 Formulations | completed | Phase 1 | 36 | AbbottINDUSTRY | 1 | Oct 7, 2010 | clinicaltrials |
| NCT00083460 | Study of Combination PS-341 and Thalidomide in Multiple Myeloma | completed | Phase 1 | 86 | University of ArkansasOTHER | 1 | Aug 2, 2010 | clinicaltrials |
| NCT00081757 |
| An Open Protocol for the Compassionate Use of Thalidomide |
| completed |
| Phase 1 / Phase 2 |
| 250 |
| University of ArkansasOTHER |
| 1 |
| Jul 2, 2010 |
| clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00021749 | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 40 | Genta IncorporatedINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00783588 | A Phase I Extension Trial of Repeated Infusions of ISF35 | completed | Phase 1 | 4 | Memgen, LLCINDUSTRY | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | completed | Phase 1 | 21 | Agenus Inc.INDUSTRY | 1 | Oct 27, 2008 | clinicaltrials |
| NCT00779883 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | completed | Phase 1 | 9 | Memgen, LLCINDUSTRY | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00001271 | A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00058656 | Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | completed | Phase 1 / Phase 2 | 18 | Xcyte TherapiesINDUSTRY | 1 | Nov 22, 2006 | clinicaltrials |
| NCT00400556 | ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells | completed | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 17, 2006 | clinicaltrials |
| NCT00036140 | Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 7, 2010source: clinicaltrials